Demonstrating the value of biologics: a call to action
Affiliations
- PMID: 23319932
- PMCID: PMC3541855
Item in Clipboard
Demonstrating the value of biologics: a call to action
Biotechnol Healthc.
2007 Aug.
Abstract
Efforts to control spending on biologics have been fragmented and inconsistent, and quality information to guide the way is scarce. How can coverage decisions be made without wasting valuable healthcare dollars, while still encouraging new development in therapies?
Similar articles
-
Capping the tax exclusion for employment-based health coverage: implications for employers and workers.EBRI Issue Brief. 2009 Jan;(325):1, 3-19. EBRI Issue Brief. 2009. PMID: 19195370
-
Pharmacy benefit spending on oral chemotherapy drugs.J Manag Care Pharm. 2006 Sep;12(7):570-7. doi: 10.18553/jmcp.2006.12.7.570. J Manag Care Pharm. 2006. PMID: 16981802 Free PMC article.
-
Financial costs associated with monopolies on biologic medicines in Australia.Aust Health Rev. 2019 Feb;43(1):36-42. doi: 10.1071/AH17031. Aust Health Rev. 2019. PMID: 29116927
-
Curbing the costly trend: exploring the need for a progressive approach to the management of specialty pharmaceuticals under the medical benefit.Am Health Drug Benefits. 2012 Jul;5(5):280-9. Am Health Drug Benefits. 2012. PMID: 24991326 Free PMC article. Review.
-
The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems.Public Health Genomics. 2019;22(1-2):8-15. doi: 10.1159/000501832. Epub 2019 Jul 22. Public Health Genomics. 2019. PMID: 31330522 Review.
References
-
- Anand G. The most expensive drugs. Wall Street Journal. 2005 Nov 15;:A1.
-
- BIO (Biotechnology Industry Organization) Approved Biotechnology Drugs. « http://www.bio.org/speeches/pubs/er/approveddrugs.asp». Accessed July 10, 2007.
-
- Carino T, Williams RD, Colbert AM, Bridger P. Medicare’s coverage of colorectal cancer drugs: a case study in evidence development and policy. Health Aff (Millwood) 2006;25:1231–1239. - PubMed
Further reading
-
- Arseneau KO, Cohn SM, Cominelli F, Connors AF., Jr Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology. 2001;120:1640–1656. - PubMed
-
- Bodger K. Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics. 2005;23:875–888. - PubMed
-
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648. - PubMed
-
- Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004;20:274–279. - PubMed
-
- Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829–1838. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous